Abrham Mulugeta Shares Insights on Tranexamic Acid: Exploring the WHO WOMAN Trial
Abrham Mulugeta, Gynecologist at Tercha General Hospital, shared on LinkedIn:
”Drug review Tranexamic Acid (TXA)
Tranexamic Acid (TXA): Life-Saving Antifibrinolytic in Postpartum Hemorrhage (PPH)
TXA is a synthetic lysine analogue that inhibits fibrinolysis — stabilizing blood clots when every minute counts.
Mechanism:
Inhibits plasminogen activation → prevents fibrin degradation → promotes stable clot formation.
Dose (as per WHO and WOMAN trial):
1 g IV over 10 min, ideally within 3 hours of birth.
Repeat once after 30 min if bleeding continues or restarts.
Indicated for:
Treatment of postpartum hemorrhage (PPH) after vaginal or cesarean delivery.
Other indications according to local guidlines.
Evidence:
WOMAN Trial (Lancet 2017)
> 20 000+ women
→ Early TXA (≤3 h) ↓ maternal death due to bleeding by ~30 %.
Side effects:
Nausea, vomiting, dizziness
Rare: thromboembolic events → use cautiously in patients with active thrombosis
Key akeaway:
TXA reduces maternal mortality when given early alongside standard PPH management (uterotonics, IV fluids, surgical measures).
Timing matters — “The sooner, the stronger the benefit.”’
Stay updated with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH